Expansion opportunity EVA Pharma has a rapidly growing footprint across the Middle East and Africa with presence in more than 60 countries and multiple manufacturing facilities. This breadth suggests potential for regional market access collaborations, contract manufacturing, and licensed distribution partnerships to accelerate penetration in new and existing therapeutic areas.

High impact therapies The portfolio focuses on twelve therapeutic areas including anti-infectives, oncology, immunotherapy and pediatrics. Opportunities exist to co-develop or co-market high-demand drugs and novel biologics, leveraging EVA Pharma’s evolving capabilities in mRNA and digital-to-biologics platforms to accelerate product readiness.

Strategic partnerships Recent collaborations with BeiGene, PharmaJet, DNA Script, Porton Advanced and Alameda Healthcare indicate a strong openness to alliances spanning biotechnology, vaccine/biologics production, and medical education. These relationships create doors for joint ventures, technology transfer, and regional manufacturing agreements.

Technology enablement EVA Pharma is building advanced capabilities in mRNA research and end-to-end RNA production platforms via international partners. This positions the company to offer next-generation vaccines and therapies, creating opportunities for technology licensing, enablement services, and integrated supply of biologics to global markets.

Scale and reliability With a large workforce, multi-facility production nearing over a million products daily, and regulatory approvals across facilities, EVA Pharma can meet high-volume demand with robust quality and supply security. Sales opportunities include large-quantity supply contracts, regional distribution agreements, and long-term procurement partnerships for government and private sector buyers.